Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04656951
Title Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (GMMG-DADA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Cologne
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.